key: cord-0886315-y3hdnwcj
authors: Paredes, Miguel I.; Lunn, Stephanie M.; Famulare, Michael; Frisbie, Lauren A.; Painter, Ian; Burstein, Roy; Roychoudhury, Pavitra; Xie, Hong; Mohamed Bakhash, Shah A.; Perez, Ricardo; Lukes, Maria; Ellis, Sean; Sathees, Saraswathi; Mathias, Patrick C.; Greninger, Alexander; Starita, Lea M.; Frazar, Chris D.; Ryke, Erica; Zhong, Weizhi; Gamboa, Luis; Threlkeld, Machiko; Lee, Jover; McDermot, Evan; Truong, Melissa; Nickerson, Deborah A.; Bates, Daniel L.; Hartman, Matthew E.; Haugen, Eric; Nguyen, Truong N.; Richards, Joshua D.; Rodriguez, Jacob L.; Stamatoyannopoulos, John A.; Thorland, Eric; Melly, Geoff; Dykema, Philip E.; MacKellar, Drew C.; Gray, Hannah K.; Singh, Avi; Peterson, JohnAric M.; Russell, Denny; Marcela Torres, Laura; Lindquist, Scott; Bedford, Trevor; Allen, Krisandra J.; Oltean, Hanna N.
title: Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study
date: 2022-04-12
journal: Clin Infect Dis
DOI: 10.1093/cid/ciac279
sha: c018ae21174a8356e7eb1e672c1d2c2f24436757
doc_id: 886315
cord_uid: y3hdnwcj

BACKGROUND: The COVID-19 pandemic is dominated by variant viruses; the resulting impact on disease severity remains unclear. Using a retrospective cohort study, we assessed the hospitalization risk following infection with seven SARS-CoV-2 variants. METHODS: Our study includes individuals with positive SARS-CoV-2 RT-PCR in the Washington Disease Reporting System with available viral genome data, from December 1, 2020 to January 14, 2022. The analysis was restricted to cases with specimens collected through sentinel surveillance. Using a Cox proportional hazards model with mixed effects, we estimated hazard ratios (HR) for hospitalization risk following infection with a variant, adjusting for age, sex, calendar week, and vaccination. FINDINGS: 58,848 cases were sequenced through sentinel surveillance, of which 1705 (2.9%) were hospitalized due to COVID-19. Higher hospitalization risk was found for infections with Gamma (HR 3.20, 95%CI 2.40-4.26), Beta (HR 2.85, 95%CI 1.56-5.23), Delta (HR 2.28 95%CI 1.56-3.34) or Alpha (HR 1.64, 95%CI 1.29-2.07) compared to infections with ancestral lineages; Omicron (HR 0.92, 95%CI 0.56-1.52) showed no significant difference in risk. Following Alpha, Gamma, or Delta infection, unvaccinated patients show higher hospitalization risk, while vaccinated patients show no significant difference in risk, both compared to unvaccinated, ancestral lineage cases. Hospitalization risk following Omicron infection is lower with vaccination. CONCLUSION: Infection with Alpha, Gamma, or Delta results in a higher hospitalization risk, with vaccination attenuating that risk. Our findings support hospital preparedness, vaccination, and genomic surveillance.

Following initial detection, SARS-CoV-2 disseminated rapidly worldwide, with the first reported 2 COVID-19 case in the United States detected in Washington State (WA) on January 19, 2020 (1). During 3 the third quarter of 2020, distinct phenotypic changes on the SARS-CoV-2 spike protein were identified, 4 raising concerns about increased transmission or greater disease severity (2). The first detections of these 5 variant viruses in WA occurred on January 23, 2021, when the first two cases of Alpha were found in 6

Snohomish County (3). 7

Since the initial detection of the first cases of the Alpha variant, multiple SARS-CoV-2 variants have 8 been reported in WA. In March 2021, the Washington State Department of Health (WADOH) partnered 9

with multiple laboratories to establish a sentinel surveillance program to monitor the genomic 10 epidemiology of SARS-CoV-2 (4). Given the replacement of ancestral lineages due to increasingly 11 greater effective reproductive numbers, variant viruses now represent the majority of sequenced cases in 12 WA (4). 13

The rapid emergence of variant viruses has resulted in numerous studies reporting increased 14 transmissibility (5-8). Previous studies have identified an increased risk of hospitalization for both Alpha 15

and Delta in various regions around the world (9-12). However, these studies compared a single variant 16

lineage to an ancestral lineage or to a small aggregated subset of variant viruses, leaving a dearth of 17 knowledge into how risk of severe disease differs among the various lineages. 18

To address this gap in knowledge regarding healthcare outcomes following infection with a variant 19

lineage, we designed a retrospective cohort study analyzing epidemiologic and genomic data from WA in 20 order to compare the risk of hospitalization among seven SARS-CoV-2 variants. 21 22

For this retrospective cohort study, we included cases with SARS-CoV-2 positive RT-PCR results in the 25

Washington Disease Reporting System (WDRS) that contained linking information to corresponding 26 sequences in the GISAID EpiCoV database (13, 14) with specimen collection dates between December 1, 27 2020 and January 14, 2022. Sequence quality was determined using Nextclade version 1.0.1 28 (https://clades.nextstrain.org/). Lineage was assigned using the Pangolin COVID-19 Lineage Assigner 29 version 3.1.20 (https://pangolin.cog-uk.io/); only cases with an assigned PANGO lineage were included. 30

The primary exposure of interest was SARS-CoV-2 variant, corresponding to all variant viruses that were 31

given a Greek letter variant label by the WHO. These were all assigned a Nextstrain clade making the 32 distinction clear (15). Variants with less than ten hospitalization events were excluded, leaving Alpha, 33

Beta, Gamma, Delta, Iota, Epsilon, and Omicron for analysis as well as ancestral viruses for reference. 34

Vaccination data was collected from the WA IIS repository that is maintained by the Office of 35

Immunizations at WADOH. 36

Cases without a known age, variant or vaccine manufacturer, cases with multiple lineages identified for 37 the same infection, and cases where the linked viral sequence had >10% sequencing ambiguity, were 38

excluded from the study. For cases with multiple specimens sequenced of the same virus, only the first 1 sequenced specimen was used for analysis. The main analysis was limited to cases with specimens 2 sequenced as part of sentinel surveillance. 3

As part of an initiative to monitor the genomic epidemiology of SARS-CoV-2, WADOH established a 5 sentinel surveillance program with partner laboratories around the state. Laboratories and the percentage 6 of randomly selected positive specimens they submit for sequencing were designated to optimize 7

representation across WA (16). Only PCR positive samples with a cycle threshold (Ct) of 30 or less are 8 selected for sequencing. In addition to these designated sentinel laboratories, specimens were classified as 9

sentinel surveillance if the sequencing laboratory indicated that they were conducting sequencing on 10 randomly selected specimens. Specimens selected for sequencing as part of outbreak investigations, 11

targeted due to travel history, targeted due to known vaccine breakthrough status, or targeted as part of 12

investigations of S-gene target failures were not considered sentinel surveillance. 13

The primary outcome of interest was COVID-19 hospitalization. COVID-19 hospitalization is defined as 15 a WA resident with confirmed COVID-19-positive lab who is identified as being hospitalized through 16 hospital records, self-report of hospitalization, or linkage with syndromic surveillance hospitalization 17 records (RHINO). If RHINO hospitalization records differ from the hospital record or self-report, the data 18

is manually reviewed to adjudicate. Cases known to be hospitalized for a condition other than COVID-19 19

(e.g. labor and delivery) are not counted. In addition to the above data curation by WADOH, we 20

additionally exclude cases where a positive viral collection date is more than 14 days after hospitalization 21 in order to prevent misclassification of hospitalizations not attributable to COVID-19. Cases with a record 22

of hospitalization but without an admission date were excluded from the study. 23

We identified a priori confounders that were suspected to be associated with both risk of hospitalization 25

following a COVID-19 infection and the epidemiological risk of acquiring a variant. These included age 26 at sampling (categorized into 10-year increments), calendar week of collection, sex assigned at birth, and 27

vaccination. Vaccination status was made into a three tier variable of 1) "Unvaccinated to <21 days post 28 dose one", 2) " ≥21 days post dose one to <21 days post booster"', 3) "≥21 days post booster" due to a 29 low number of hospitalized cases having a record of vaccination. We consider active vaccination only 30 after 21 days due to CDC guidance regarding active protection from symptomatic infection only after 14 31 days (17) and then allowing for an additional 7 days to allow for the development of protection from 32 hospitalization, given that the mean time from symptom onset to hospitalization was found to be about 7 33

days (18) . Our vaccination covariate includes cases with a history of vaccination with BNT162b2 , 34 mRNA-1273, and Ad26.COV2. Additionally, cases with a repeat positive test (defined as a case where 35 the specimen collection date was more than 21 days after the first positive test date) were also excluded 36 from the study to reduce confounding from previous immunity. 37

We used descriptive statistics to explore characteristics of our sample stratified by SARS-CoV-2 lineage. 2

For all descriptive analyses, we summarized categorical variables as frequencies and percentages. 3

We estimated the associations between SARS-CoV-2 variants and the risk of COVID-19 hospitalization 4 by calculating hazard ratios (HRs) for the time to hospital admission through a Cox proportional hazard 5 model with mixed effects using ancestral lineages as the reference group. We adjusted the HRs for the 6 covariates of age, sex assigned at birth, calendar week (continuous), and vaccination status. Sex and 7

vaccination status were added as random effects to regularize adjustments for under-represented 8 categories. A likelihood ratio test was used to examine the global effect of variant lineages on 9 hospitalization risk. 10

In a secondary analysis to analyze how vaccination affected the risk of hospitalization by variant lineage, 11

an interaction term of vaccination*lineage was introduced into the model and reran for those variants 12

found to have the largest sample size and effect magnitude: Alpha, Gamma, Delta, and Omicron.

Stratified risk of hospitalization by vaccination status was conditioned on the "Unvaccinated to <21 days 14 post dose one" group for cases infected with an ancestral lineage. 15

The above analysis was repeated with a subset of the data only including cases infected with Delta (as the 16 reference) or Omicron with a collection date after September 1st, 2021. 17

In order to account for differences in both model selection and case inclusion, sensitivity analyses were 18 performed using a Cox proportional hazard model with fixed effects and a Poisson regression model for 19

both the subsetted sentinel surveillance-only dataset as well as for the entire case dataset found in WDRS 20

for the same study period. Statistical analyses were performed using R version 3.6.2 (R Project for 21

Statistical Computing). 22

Analytic code can be found at https://github.com/blab/ncov-wa-variant-severity 23

The COVID-19 epidemic in WA shows a distinct trend in the lineage distribution over time (Fig. 1) . 25

Early on, the epidemic was predominantly characterized by ancestral lineages, while by March 2021, 26 SARS-CoV-2 variants gained predominance over ancestral lineages. 27

In this study, we included 63,639 cases with viral genome data available on WDRS, with specimens 28 collected from December 1, 2020 to January 14, 2022 (Fig. S1 ). Of these, the final study population for 29 the main analysis was restricted to 58,848 (92.3%) cases that were part of sentinel surveillance. The 30

proportion of total cases in WA that were sequenced as part of sentinel surveillance over time is shown in 31 Fig. S2 . 32 95% CI 1.29-2.07) also showed a higher risk of hospitalization when compared to the reference. All other 5 variants, including Omicron (HR 0.92, 95% CI 0.56-1.52) failed to show a significant difference in risk of 6 hospitalization (Table 2) . 7

The association between variant lineage and hospitalization risk stratified by vaccination is shown in 8 Figure 3 with unvaccinated individuals (unvaccinated or <21 days post dose one) infected with ancestral 9

lineages as the reference category. When compared to the reference, our model shows a higher risk of 10 hospitalization for those unvaccinated individuals infected with Gamma, Delta, or Alpha, while those 11

infected with Omicron showed no significant difference (Table 3 ). In the strata of individuals with an 12

active vaccination but no active booster, no significant difference was observed in the risk of hospital 13

admittance following infection with Gamma, Delta, or Alpha, but a lower risk of hospitalization was 14

found In a secondary analysis comparing hospitalization risk following infection with Omicron to infection with 24

Delta as the reference (Fig 4, Table S2 ), we find a lower risk of hospitalization associated with Omicron 25 infection (HR 0.34, 95% CI 0.23-0.50). When stratified by vaccination status, we find progressively lower 26 risks of hospitalization for cases infected with Omicron for those unvaccinated (HR 0.37, 95% CI 0.21-27 0.66), vaccinated without a booster (HR 0.23, 95% CI 0.14-0.39), and those ≥21 days post booster (HR 28 0.19, 95% CI 0.09-0.41), all when compared to unvaccinated cases with Delta infections. 29

Estimates of the HR of the risk of hospitalization for cases infected with variants are robust to both model 30 selection and inclusion of all sequences in our original database (Supp. Fig. 3-4) . 31

In this study, we use SARS-CoV-2 cases in WA that were sequenced as part of sentinel surveillance to 33 evaluate the differential risk of hospitalization following infection with a variant. We find that in our 34 study period, cases infected with Alpha, Beta, Gamma, or Delta have a higher hospitalization risk 35 compared to cases infected with an ancestral lineage, after adjusting for relevant covariates. We find 36 similar estimates of higher hospitalization risk in the subset of unvaccinated individuals and no significant 37 difference in hospitalization risk in individuals with an active vaccination, following infection with 38

Gamma, Delta, or Alpha, while individuals infected with Omicron show a lower hospitalization risk in all 39

vaccination categories, all compared to unvaccinated individuals infected with ancestral lineages. 40 with Delta when compared to those infected with Alpha, together suggesting that vaccination exerts a 20 similar effect across these three variants (11,25). Unvaccinated individuals infected with Omicron showed 21 no significant difference in risk of hospitalization, but individuals with any vaccination were found to 22

have a lower hospitalization risk, all when compared to the unvaccinated, ancestral reference. When 23

comparing hospitalization risk of Omicron vs Delta stratified by vaccination status, we find that any 24 active vaccination is associated with a lower risk of hospitalization regardless of lineage when compared 25

to unvaccinated cases with Delta infections, with estimates of risk similarly observed in Denmark (21). 26

Our sample sizes in some stratum are small (Table S1 ) limiting our ability to make conclusions. 27

Additionally, cases were selected into our study based on test positivity; if vaccinated individuals are less 28 likely to seek testing and severe illness leads to increased testing, conditioning study enrollment on 29

testing can lead to collider stratification bias, or a distorted association between vaccination and disease 30 severity (26). Prior to July 27, 2021, CDC guidance stated that fully vaccinated individuals without 31 symptoms did not need to get laboratory tested for SARS-CoV-2 following an exposure, meaning that 32 cases in our sample with a vaccination record, which are conditional on being tested, are almost certainly 33

biased towards a subset of the population with a more severe clinical presentation than the population at-34 large, potentially underestimating estimates of vaccine protection on hospitalization risk. However, Delta 35

and Omicron estimates largely derive from cases and hospitalizations after July 27, 2021. 36

Although our findings are consistent with previous studies, they are not without limitations. Variant 37 classification is conditional on whole genome sequencing and a Ct threshold <30, meaning that our 38 sequenced cohort may have been different from the general population of cases in WA. Sample sizes 39

were determined by variant-specific circulation in WA and thus some variant categories have as few as 11 40

hospitalizations (Table 1 : Beta); these respective estimates should be interpreted accordingly. Vaccination 41 data in IIS is not comprehensive of federal vaccination efforts; vaccination status may therefore be 42

misclassified for some cases. Sentinel specimens included in this study were randomly selected for 1 sequencing within laboratories, but laboratories were not randomly sampled for inclusion in the sentinel 2 surveillance program. The implementation of this program set proportions for sampling from specific 3 laboratories to gather a geographically representative sample. It is possible that laboratory-level 4 association with patient populations with differential risk of hospitalization over time may bias the study 5

findings. The study is observational in nature, meaning that despite adjusting for potential confounders, 6

there might be other confounders such as use of monoclonal therapy, social deprivation, etc., that might 7 affect the association between SARS-CoV-2 variant and hospitalization risk. While previous studies have 8

included comorbid conditions, race/ethnicity, or region of residence, their association with the risk of 9

infection with a variant vs an ancestral strain in WA is unclear and thus were not included in our a priori 10 set of confounders. Including these variables in an exploratory model did not affect estimates (Delta 11

adjusting for race and county: HR 2.21 95% CI 1.50-3.30; Delta without race and county: HR 2.28 95% 12 CI 1.56-3.34). 13

In conclusion, our retrospective cohort study found a higher hospitalization risk in cases infected with 14

Alpha, Beta, Gamma, and Delta, but not Omicron. Our study supports hospital preparedness in areas with 15

uncontrolled viral spread as well as promoting vaccination. This study also highlights the importance of 16

ongoing genomic surveillance at the state and federal level to monitor variant outcomes. Building a robust 17

public health workforce as well as collaborations between public health and academia is critical to using 18

genomic epidemiology to answer crucial questions about emerging SARS-CoV-2 variants. 19

Clinical and sentinel laboratories who forwarded specimens for sequencing, and sequencing laboratories 22

that reported data to WADOH. The WADOH Data Science Support Unit for integrating sequencing data 23

with epidemiologic case data. UW Virology Lab was approved by the University of Washington Institutional Review Board (protocol 8 STUDY00000408). 9

Requests to access these data are handled by the Washington Department of Health. 11 

Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian

Public Health England. SARS-CoV-2 variants of concern and variants under investigation

Clinical outcomes among 16 patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California

Hospitalisation Associated With Infection With SARS-CoV-2 Omicron Relative to Delta: A Danish 21

SARS-CoV-2 Variant Is Associated With Reduced Risk of Hospitalization and Length of Stay 25

Compared With Delta (B.1.617.2)

CoV-2 P.1 introduction and the impact of COVID-19 vaccination on the epidemiological landscape 30 of São José Do Rio Preto, Brazil [Internet]. Infectious Diseases (except HIV/AIDS)

Characteristics of SARS-CoV-2 33 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries

Hospital 36 admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with 37 alpha (B.1.1.7) variants of concern: a cohort study

Collider bias undermines 41 our understanding of COVID-19 disease risk and severity